MersV1, France, Analysis, bibRecord, 000290

In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate

Identifieur interne : 000290 ( France/Analysis ); précédent : 000289; suivant : 000291

In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate

Auteurs : Mazurier [France]

Source :

Haemophilia [ 1351-8216 ] ; 1998-11.

RBID : ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC

Descripteurs français

KwdFr :
- Collagène (métabolisme), Complexe glycoprotéique GPIb-IX plaquettaire, Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire (métabolisme), Facteur VIII (métabolisme), Facteur de von Willebrand (analyse), Facteur de von Willebrand (métabolisme), Glycoprotéines de membrane plaquettaire, Humains, Hémostatiques (analyse), Hémostatiques (métabolisme), Récepteurs de surface cellulaire (métabolisme).
MESH :
- analyse : Facteur de von Willebrand, Hémostatiques.
- métabolisme : Collagène, Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire, Facteur VIII, Facteur de von Willebrand, Hémostatiques, Récepteurs de surface cellulaire.
- Complexe glycoprotéique GPIb-IX plaquettaire, Glycoprotéines de membrane plaquettaire, Humains.

English descriptors

KwdEn :
- Collagen (metabolism), Factor VIII (metabolism), Hemostatics (analysis), Hemostatics (metabolism), Humans, Platelet Glycoprotein GPIIb-IIIa Complex (metabolism), Platelet Glycoprotein GPIb-IX Complex, Platelet Membrane Glycoproteins, Receptors, Cell Surface (metabolism), von Willebrand Factor (analysis), von Willebrand Factor (metabolism).
MESH :
- chemical , analysis : Hemostatics, von Willebrand Factor.
- chemical , metabolism : Collagen, Factor VIII, Hemostatics, Platelet Glycoprotein GPIIb-IIIa Complex, Receptors, Cell Surface, von Willebrand Factor.
Teeft :
- Agarose, Assay, Blackwell science, Cofactor, Cryoprecipitate, Different fractions, Different lots, Electrophoretic, Factor viii, Functional integrity, Fviii, Goudemand, Haemophilia, Haemostatic, Haemostatic value, High purity, Humans, Laboratoire francais, Mazurier, Multimeric, Multimeric pattern, Multimers, Native plasma, Normal plasmas, Platelet, Platelet Glycoprotein GPIb-IX Complex, Platelet Membrane Glycoproteins, Platelet adhesion, Preclinical, Preclinical development, Quality control, Quantitative evaluation, Rectangular perfusion chamber system, Ristocetin, Ristocetin cofactor activity, Suppl, Therapeutic lots, Thromb, Thromb haemost, Various multimers, Viii, Willebrand, Willebrand disease, Willebrand disease patients, Willebrand factor.

Abstract

The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.

Url:

https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.pdf

DOI: 10.1046/j.1365-2516.1998.0040s3040.x

Affiliations:

Links to Exploration step

ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title>
<author><name sortKey="Mazurier" sort="Mazurier" uniqKey="Mazurier" first="" last="Mazurier">Mazurier</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1046/j.1365-2516.1998.0040s3040.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-SRXBTGD4-5/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000068</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000068</idno>
<idno type="wicri:Area/Istex/Curation">000068</idno>
<idno type="wicri:Area/Istex/Checkpoint">001365</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001365</idno>
<idno type="wicri:doubleKey">1351-8216:1998:Mazurier:in:vitro:evaluation</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10028317</idno>
<idno type="wicri:Area/PubMed/Corpus">002646</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002646</idno>
<idno type="wicri:Area/PubMed/Curation">002646</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002646</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002528</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002528</idno>
<idno type="wicri:Area/Ncbi/Merge">000002</idno>
<idno type="wicri:Area/Ncbi/Curation">000002</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000002</idno>
<idno type="wicri:doubleKey">1351-8216:1998:Mazurier C:in:vitro:evaluation</idno>
<idno type="wicri:Area/Main/Merge">003C05</idno>
<idno type="wicri:Area/Main/Curation">003B55</idno>
<idno type="wicri:Area/Main/Exploration">003B55</idno>
<idno type="wicri:Area/France/Extraction">000290</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate</title>
<author><name sortKey="Mazurier" sort="Mazurier" uniqKey="Mazurier" first="" last="Mazurier">Mazurier</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Développement Pré‐Clinique, Laboratoire Français du Fractionnement et des Biotechnologies, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Haemophilia</title>
<title level="j" type="alt">HAEMOPHILIA</title>
<idno type="ISSN">1351-8216</idno>
<idno type="eISSN">1365-2516</idno>
<imprint><biblScope unit="vol">4</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="page" from="40">40</biblScope>
<biblScope unit="page" to="43">43</biblScope>
<biblScope unit="page-count">4</biblScope>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford UK</pubPlace>
<date type="published" when="1998-11">1998-11</date>
</imprint>
<idno type="ISSN">1351-8216</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-8216</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Collagen (metabolism)</term>
<term>Factor VIII (metabolism)</term>
<term>Hemostatics (analysis)</term>
<term>Hemostatics (metabolism)</term>
<term>Humans</term>
<term>Platelet Glycoprotein GPIIb-IIIa Complex (metabolism)</term>
<term>Platelet Glycoprotein GPIb-IX Complex</term>
<term>Platelet Membrane Glycoproteins</term>
<term>Receptors, Cell Surface (metabolism)</term>
<term>von Willebrand Factor (analysis)</term>
<term>von Willebrand Factor (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Collagène (métabolisme)</term>
<term>Complexe glycoprotéique GPIb-IX plaquettaire</term>
<term>Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire (métabolisme)</term>
<term>Facteur VIII (métabolisme)</term>
<term>Facteur de von Willebrand (analyse)</term>
<term>Facteur de von Willebrand (métabolisme)</term>
<term>Glycoprotéines de membrane plaquettaire</term>
<term>Humains</term>
<term>Hémostatiques (analyse)</term>
<term>Hémostatiques (métabolisme)</term>
<term>Récepteurs de surface cellulaire (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Hemostatics</term>
<term>von Willebrand Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Collagen</term>
<term>Factor VIII</term>
<term>Hemostatics</term>
<term>Platelet Glycoprotein GPIIb-IIIa Complex</term>
<term>Receptors, Cell Surface</term>
<term>von Willebrand Factor</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Facteur de von Willebrand</term>
<term>Hémostatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Collagène</term>
<term>Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire</term>
<term>Facteur VIII</term>
<term>Facteur de von Willebrand</term>
<term>Hémostatiques</term>
<term>Récepteurs de surface cellulaire</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Agarose</term>
<term>Assay</term>
<term>Blackwell science</term>
<term>Cofactor</term>
<term>Cryoprecipitate</term>
<term>Different fractions</term>
<term>Different lots</term>
<term>Electrophoretic</term>
<term>Factor viii</term>
<term>Functional integrity</term>
<term>Fviii</term>
<term>Goudemand</term>
<term>Haemophilia</term>
<term>Haemostatic</term>
<term>Haemostatic value</term>
<term>High purity</term>
<term>Humans</term>
<term>Laboratoire francais</term>
<term>Mazurier</term>
<term>Multimeric</term>
<term>Multimeric pattern</term>
<term>Multimers</term>
<term>Native plasma</term>
<term>Normal plasmas</term>
<term>Platelet</term>
<term>Platelet Glycoprotein GPIb-IX Complex</term>
<term>Platelet Membrane Glycoproteins</term>
<term>Platelet adhesion</term>
<term>Preclinical</term>
<term>Preclinical development</term>
<term>Quality control</term>
<term>Quantitative evaluation</term>
<term>Rectangular perfusion chamber system</term>
<term>Ristocetin</term>
<term>Ristocetin cofactor activity</term>
<term>Suppl</term>
<term>Therapeutic lots</term>
<term>Thromb</term>
<term>Thromb haemost</term>
<term>Various multimers</term>
<term>Viii</term>
<term>Willebrand</term>
<term>Willebrand disease</term>
<term>Willebrand disease patients</term>
<term>Willebrand factor</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Complexe glycoprotéique GPIb-IX plaquettaire</term>
<term>Glycoprotéines de membrane plaquettaire</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The structural and functional studies of the concentrate of von Willebrand factor (vWF) manufactured by LFB have been first performed as part of the preclinical development of this product specially intended for the treatment of von Willebrand disease. The electrophoretic analyses showed the high purity of LFB‐vWF concentrate (specific activity of 100 IU of ristocetin cofactor activity per milligram of protein) and the multimeric pattern attesting the presence of high molecular weight multimeters (≥15‐mers). The measurements of vWF capacity to bind to: (1) platelet glycoprotein (GP) Ib in the presence of ristocetin; (2) GPIIb/IIIa in the presence of thrombin; (3) types I and III collagen; (4) factor VIII (FVIII) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF. Furthermore the LFB‐vWF concentrate was able to promote platelet adhesion to collagen. The release of the therapeutic batches of this product rely presently on their potency measured with the ristocetin cofactor activity (40–70 IU ml−1) and the quantitative evaluation of vWF multimeric distribution studied using electrophoresis in 1.5% agarose. These validated techniques ensure the consistency and haemostatic properties of the different lots of LFB‐vWF concentrate.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
</region>
<settlement><li>Lille</li>
</settlement>
</list>
<tree><country name="France"><region name="Hauts-de-France"><name sortKey="Mazurier" sort="Mazurier" uniqKey="Mazurier" first="" last="Mazurier">Mazurier</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000290 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000290 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:A426110A51A47360E86467CF7D76CAFD62D6DBCC
   |texte=   In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

Serveur d'exploration MERS

In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate

In vitro evaluation of the haemostatic value of the LFB‐von Willebrand factor concentrate

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.